SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-012561
Filing Date
2022-08-08
Accepted
2022-08-08 11:44:14
Documents
54
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q anvs-20220630x10q.htm   iXBRL 10-Q 759987
2 EX-31.1 anvs-20220630xex31d1.htm EX-31.1 13511
3 EX-31.2 anvs-20220630xex31d2.htm EX-31.2 13545
4 EX-32.1 anvs-20220630xex32d1.htm EX-32.1 5705
5 EX-32.2 anvs-20220630xex32d2.htm EX-32.2 5691
  Complete submission text file 0001558370-22-012561.txt   3393500

Data Files

Seq Description Document Type Size
6 EX-101.SCH anvs-20220630.xsd EX-101.SCH 29136
7 EX-101.CAL anvs-20220630_cal.xml EX-101.CAL 22318
8 EX-101.DEF anvs-20220630_def.xml EX-101.DEF 87078
9 EX-101.LAB anvs-20220630_lab.xml EX-101.LAB 257859
10 EX-101.PRE anvs-20220630_pre.xml EX-101.PRE 175464
48 EXTRACTED XBRL INSTANCE DOCUMENT anvs-20220630x10q_htm.xml XML 471580
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39202 | Film No.: 221143239
SIC: 2834 Pharmaceutical Preparations